Susquehanna International Group’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-23,500
Closed -$68K 14369
2021
Q3
$68K Sell
23,500
-41,100
-64% -$137K ﹤0.01% 12241
2021
Q2
$225K Sell
64,600
-13,300
-17% -$45.7K ﹤0.01% 11343
2021
Q1
$266K Buy
77,900
+300
+0.4% +$5.67K ﹤0.01% 10855
2020
Q4
$1.49M Buy
77,600
+60,900
+365% +$940K ﹤0.01% 5756
2020
Q3
$224K Buy
16,700
+11,700
+234% +$331K ﹤0.01% 9281
2020
Q2
$212K Buy
+5,000
New +$162K ﹤0.01% 8940

Other funds holding ODT

Susquehanna International Group's ODT Position: Q4 2021 in Review

Susquehanna International Group sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q4 2021, closing a stake of 35,475 shares — an estimated $103K sold.

Susquehanna International Group first reported a position in ODT in Q1 2020 and held it in 6 quarters. The position peaked at $1.08M in Q4 2020. 50 funds tracked by Wall St. Rank hold ODT as of Q4 2021.

  • Susquehanna International Group reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Susquehanna International Group sold 35,475 Odonate Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $103K.
  • Susquehanna International Group first reported a position in Odonate Therapeutics, Inc. Common Stock in Q1 2020 and held it in 6 quarters.
  • Susquehanna International Group's Odonate Therapeutics, Inc. Common Stock position peaked at $1.08M in Q4 2020.
  • 50 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Susquehanna International Group's 13F filing for Q4 2021, filed 14 Feb 2022.